Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys

Suresh K. Balani, Tong Zhu, Tian J. Yang, Zhi Liu, Bing He, Frank W. LeeDrug 2002 · DOI

TL;DR

This study establishes a reliable dosing regimen for 1-aminobenzotriazole (ABT), a common P450 inhibitor, to effectively and safely probe drug metabolism in rats, dogs, and monkeys. By characterizing ABT's pharmacokinetics and its in vitro inhibition of key P450 enzymes, the authors provide crucial guidelines for its use in mechanistic toxicology studies.

What Problem Does This Paper Address?

Understanding how drugs are metabolized by the body is critical for drug development and safety assessment. A key player in this process are the cytochrome P450 (P450) enzymes, a family of proteins responsible for breaking down a vast array of foreign compounds, including drugs. To study the role of these enzymes, researchers often use inhibitors like 1-aminobenzotriazole (ABT) to temporarily "turn off" P450 activity. However, the way ABT has been used in different labs has been inconsistent, leading to variable results. This variability stems from a lack of clear understanding of ABT's own behavior in the body (its pharmacokinetics) and how effectively it inhibits various P450 enzymes. This paper aims to bridge this knowledge gap by providing a standardized and effective dosing strategy for ABT in common preclinical species.

Methods

The researchers employed a multi-pronged approach:

  • Oral Pharmacokinetic Studies: They administered ABT orally to rats, dogs, and monkeys at various doses (5-200 mg/kg) and collected blood samples over time to measure ABT concentrations. This allowed them to understand how quickly ABT was absorbed, distributed, and eliminated.
  • In Vitro P450 Inhibition Assays: They used "supersomes" (recombinant human P450 enzymes expressed in a lab setting) and incubated them with ABT at different concentrations. By measuring the activity of specific P450 enzymes (like CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A4) in the presence of ABT, they determined which enzymes were inhibited and at what concentrations.
  • In Vivo Drug Metabolism Studies: They pretreated animals with ABT and then administered antipyrine (AP), a well-established probe drug for measuring overall hepatic oxidative metabolism. By measuring AP's concentration in the blood over time, they could quantify how ABT pretreatment affected AP's clearance (how quickly it was removed from the body), which directly reflects P450 activity.
  • LC-MS/MS Analysis: A liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was used to simultaneously quantify ABT and AP in plasma samples, ensuring accurate and sensitive measurements.

Datasets

Not discussed in the paper. The study utilized animals (rats, dogs, monkeys) and commercially available recombinant human P450 supersomes.

Key Insights and Ideas

  • ABT's Sustained Plasma Levels: A single oral dose of ABT, particularly at doses of 50 mg/kg in rats and 20 mg/kg in dogs and monkeys, leads to high and sustained plasma concentrations for over 24 hours. This is crucial because it suggests a single dose can provide prolonged P450 inhibition.
  • Broad P450 Inhibition Profile: ABT effectively inhibits a wide range of human P450 isoforms in vitro, including CYP1A2, 2B6, 2C9, 2C19, 2D6, and 3A4, in a dose-dependent manner. This confirms its utility as a broad-spectrum P450 inhibitor.
  • Antipyrine as a Reliable Probe: Antipyrine's properties (low hepatic extraction, low protein binding, and near-complete metabolism by P450s) make it an excellent probe to assess the impact of P450 inhibition on overall drug metabolism.
  • Effective Pretreatment Strategy: A 2-hour pretreatment with ABT before administering a probe drug like antipyrine is sufficient to achieve significant inhibition of P450-mediated clearance.

Key Results

  • Significant Antipyrine Clearance Inhibition:
    • In rats, a 50 mg/kg oral dose of ABT inhibited antipyrine clearance by approximately 88%.
  • In dogs, a 20 mg/kg oral dose of ABT inhibited antipyrine clearance by approximately 96%.
  • In monkeys, a 20 mg/kg oral dose of ABT inhibited antipyrine clearance by approximately 83%.
  • Recommended Dosing Regimen: Based on these findings and ABT's safety profile, the authors recommend a single oral dose of ABT at 100 mg/kg in rats and 20 mg/kg in dogs and monkeys, administered 2 hours prior to the test compound, for effective P450 inhibition.
  • Dose-Proportional Increase in AUC: The area under the curve (AUC) for ABT increased in a greater than dose-proportional manner, indicating complex pharmacokinetic behavior at higher doses.

Limitations and Future Work

  • Species-Specific PK: While the study characterized ABT pharmacokinetics in rats, dogs, and monkeys, detailed PK data for all species at all tested doses were not fully presented (e.g., some AUC values were for 60h instead of 72h).
  • Chronic Toxicity Data: While ABT is known to be safe in rats at high doses, chronic toxicity data in dogs and monkeys are not as extensively reported, though the authors note its safe use in their labs for mechanistic studies.
  • Future Work: The authors suggest that for compounds with high hepatic extraction ratios that are cleared primarily through oxidative metabolism, lower ABT doses might be sufficient. They also emphasize that a single oral dose pretreatment is effective and can replace multiple dosing strategies for mechanistic studies. Further investigation into the optimal pretreatment times for different P450 isoforms could also be beneficial.

Summary updated

BibTeX
@inproceedings{balani2002effective,
  author = {Suresh K. Balani and Tong Zhu and Tian J. Yang and Zhi Liu and Bing He and Frank W. Lee},
  title = {{Effective Dosing Regimen of 1-Aminobenzotriazole for Inhibition of Antipyrine Clearance in Rats, Dogs, and Monkeys}},
  booktitle = {Drug},
  year = {2002},
  doi = {10.1124/dmd.30.10.1059},
}
Figure